How to buy ACADIA Pharmaceuticals stock (ACAD)

ACADIA Pharmaceuticals is a biotechnology business based in the US. ACADIA Pharmaceuticals shares (ACAD) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $16.87 – a decrease of 2.26% over the previous week. ACADIA Pharmaceuticals employs 620 staff and has a trailing 12-month revenue of around $929.2 million.

Our top picks for where to buy ACADIA Pharmaceuticals stock

Buy ACADIA Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

ACADIA Pharmaceuticals stock price (NASDAQ: ACAD)

Use our graph to track the performance of ACAD stocks over time.

ACADIA Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$16.87
52-week range	$14.15 - $32.59
50-day moving average more info button	$16.08
200-day moving average more info button	$16.61
Wall St. target price	$25.11
PE ratio more info button	21.6795
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.78

Is it a good time to buy ACADIA Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ACADIA Pharmaceuticals price performance over time

Historical closes compared with the close of $16.73 from 2024-12-19

1 week (2024-12-12)	-3.07%
1 month (2024-11-21)	3.40%
3 months (2024-09-19)	1.89%
6 months (2024-06-21)	9.35%

1 year (2023-12-21)	-43.33%
2 years (2022-12-21)	9.27%
3 years (2021-12-21)	21.45
5 years (2019-12-20)	45.19

Is ACADIA Pharmaceuticals stock undervalued or overvalued?

Valuing ACADIA Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ACADIA Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ACADIA Pharmaceuticals's P/E ratio

ACADIA Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, ACADIA Pharmaceuticals shares trade at around 22x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

ACADIA Pharmaceuticals's EBITDA

ACADIA Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $124.5 million.

The EBITDA is a measure of a ACADIA Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

ACADIA Pharmaceuticals financials

Revenue TTM	$929.2 million
Operating margin TTM	12.64%
Gross profit TTM	$145.5 million
Return on assets TTM	8.72%
Return on equity TTM	27.36%
Profit margin	13.83%
Book value	$3.47
Market Capitalization more info button	$2.8 billion

TTM: trailing 12 months

ACADIA Pharmaceuticals share dividends

We're not expecting ACADIA Pharmaceuticals to pay a dividend over the next 12 months.

ACADIA Pharmaceuticals share price volatility

Over the last 12 months, ACADIA Pharmaceuticals's shares have ranged in value from as little as $14.15 up to $32.59. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ACADIA Pharmaceuticals's is 0.379. This would suggest that ACADIA Pharmaceuticals's shares are less volatile than average (for this exchange).

ACADIA Pharmaceuticals overview

ACADIA Pharmaceuticals Inc. , a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc.

Frequently asked questions

null
What percentage of ACADIA Pharmaceuticals is owned by insiders or institutions?
Currently 0.547% of ACADIA Pharmaceuticals shares are held by insiders and 97.501% by institutions. How many people work for ACADIA Pharmaceuticals?
Latest data suggests 620 work at ACADIA Pharmaceuticals. When does the fiscal year end for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals's fiscal year ends in December. Where is ACADIA Pharmaceuticals based?
ACADIA Pharmaceuticals's address is: 12830 El Camino Real, San Diego, CA, United States, 92130 What is ACADIA Pharmaceuticals's ISIN number?
ACADIA Pharmaceuticals's international securities identification number is: US0042251084 What is ACADIA Pharmaceuticals's CUSIP number?
ACADIA Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 004225108